相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: Comparison with a controlled clinical trial
Arthur Wheeler et al.
CRITICAL CARE MEDICINE (2008)
Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008
R. Phillip Dellinger et al.
CRITICAL CARE MEDICINE (2008)
Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock
Simon Finfer et al.
INTENSIVE CARE MEDICINE (2008)
Effectiveness of influenza vaccine in the community-dwelling elderly
Kristin L. Nichol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study
Sari Karlsson et al.
INTENSIVE CARE MEDICINE (2007)
Analysis of observational studies in the presence of treatment selection bias - Effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods
Therese A. Stukel et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Drug therapy: Management of sepsis
Jarnes A. Russell
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Activated protein C (Xigris®) treatment in sepsis:: a drug in trouble
B. Gardlund
ACTA ANAESTHESIOLOGICA SCANDINAVICA (2006)
Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect
T Kurth et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2006)
Use of an integrated clinical trial database to evaluate the effect of timing of drotrecogin alfa (activated) treatment in severe sepsis
Jean-Louis Vincent et al.
CRITICAL CARE (2006)
The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database
David A. Harrison et al.
CRITICAL CARE (2006)
Dyotyecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment
JL Vincent et al.
CRITICAL CARE MEDICINE (2005)
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
E Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units
S Finfer et al.
INTENSIVE CARE MEDICINE (2004)
Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US) - A single-arm, phase 313, multicenter study of drotrecogin alfa (activated) in severe sepsis
GR Bernard et al.
CHEST (2004)
The epidemiology of sepsis in the United States from 1979 through 2000
GS Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Validity of information on comorbidity derived from ICD-9-CCM administrative data
HD Quan et al.
MEDICAL CARE (2002)
Comparison of evidence of treatment effects in randomized and nonrandomized studies
JPA Ioannidis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
DC Angus et al.
CRITICAL CARE MEDICINE (2001)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
A comparison of observational studies and randomized, controlled trials.
K Benson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Randomized, controlled trials, observational studies, and the hierarchy of research designs.
J Concato et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
